Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients – in Real-World Clinical Practice

Best Practice Nordic | Joulu 2018 | ASH 2018 |

Real-world evidence from the Belgian registry shows that ponatinib has a favorable efficacy and safety profile in, and supports its use in CML and Ph+ ALL patients who are resistant or intolerant to previous therapies or those with the T315I mutation. Deep molecular responses were obtained in the majority of patients. No new safety signals emerged with ponatinib treatment than those previously reported.